Market Introduction
Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.
Market Overview and Dynamics
The Asia Pacific anti-viral therapies market is expected to reach US$ 16,118.52 million by 2027 from US$ 8,135.93 million in 2019; it is anticipated to grow at a CAGR of 9.0% during 2020–2027.The growth of the market is attributed to the increasing prevalence of viral diseases and outbreak of COVID-19 pandemic, growing R&D expenditures of pharmaceutical companies, and rising government support for research activities and clinical trials. However, high cost of drug development obstructs the growth of the market to a certain extent.
Key Market Segments
In terms of type, the branded drugs segment accounted for a larger share of the Asia Pacific anti-viral therapies market in 2019. In terms of mechanism of action, the nucleotide polymerase inhibitors segment accounted for the largest share of the market in 2019. In terms of application, the HIV segment accounted for the largest share of the Asia Pacific anti-viral therapies market in 2019.
Major Sources and Companies Listed
Several major primary and secondary sources associated with the Asia Pacific anti-viral therapies market report are the World Health Organization (WHO), International Society for Pharmaceutical Engineering, China Food and Drug Administration (CFDA), National Health Commission (NHC) of China, India Brand Equity Foundation (IBEF), and others.
Reasons to Buy Report
- It provides understanding of the Asia Pacific, anti-viral therapies market landscape and identifies anti-viral therapies market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific anti-viral therapies market.
- It helps efficiently plan merger and acquisition, and partnership deals in the anti-viral therapiesmarket by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of anti-viral therapies market performance of various segments pertaining to the Asia Pacificanti-viral therapies market.
- It provides anti-viral therapies market revenue forecast of the market based on various segments for the period from 2019 to 2027.
ASIA PACIFIC ANTI-VIRAL THERAPIESMARKET SEGMENTATION
By Type
- Branded Drugs
- Generic Drugs
By Mechanism of Action
- Nucleotide Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Application
- HIV
- Hepatitis
- Virus Influenza
- Herpes
- Others
By Country
- China
- Japan
- India
- South Korea
- Australia
Company Profiles
- Aurobindo Pharma Ltd
- AbbVie Inc.
- GlaxoSmithKline plc
- AstraZeneca
- F. HOFFMANN-LA ROCHE LTD
Asia Pacific Anti-Viral Therapies Market Strategic Insights
Asia Pacific Anti-Viral Therapies Market Report Highlights
| Report Attribute | Details |
| Market size in 2019 | US$ 8,135.93 Million |
| Market Size by 2027 | US$ 16,118.52 Million |
| CAGR (2020 - 2027) | 9.0% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
Asia Pacific Anti-Viral Therapies Market Country and Regional Insights
